Nicotinamide Riboside for Health & Longevity - Quick Reference Sheet

Nicotinamide Riboside for Health & Longevity

Created on 07/09/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A form of vitamin B3 that the body converts into an essential coenzyme for energy and DNA repair, which declines with age. It reliably raises this coenzyme in the blood without flushing, but whether that improves health is uncertain: blood pressure and inflammation signals are promising yet inconsistent. Safety looks reassuring, with mild, infrequent side effects. (Full Review)

Protocol

Standard Dose
250–500 mg
Once daily; some titrate toward 1,000 mg/day
Best Time of Day
Morning
Practitioner convention; timing evidence weak
Dosing Schedule
Once daily
Splitting may aid GI tolerability at higher doses
Time to effect
Blood NAD+ Rise
Hours to days
Plateaus over 1–2 weeks
Blood Pressure
6–12 weeks
Mainly in those starting elevated
Inflammation
6–12 weeks
Where an effect occurs

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Active malignancy (without oncology oversight)
  • Significant liver impairment (e.g., decompensated cirrhosis)
Key Interactions
  • Other NAD+ precursors (niacin, nicotinamide, NMN, NADH)
  • Methyl-donor supplements (betaine, folate, vitamin B12, choline)
  • OTC B3 products (high-dose niacin, NAD-booster blends)
  • Chemotherapy and cancer therapies (cisplatin, doxorubicin, NAMPT inhibitors)
  • Antihypertensive medications (ACE inhibitors, ARBs, calcium channel blockers, diuretics)

Risk & Side Effects

  • High: Mild, transient adverse effects
  • Medium: Increased methyl-group consumption and methylated metabolites
  • Low: Elevated liver enzymes and hepatic stress
  • Speculative: Potential promotion of existing cancers; uncharacterized long-term effects of sustained NAD+ elevation

Monitoring

Marker Target Why
Whole-blood NAD+ Individualized (rise from personal baseline) Confirms the supplement is doing its core job
hs-CRP < 1.0 mg/L Tracks whether inflammation, where elevated, improves
Homocysteine 6–8 µmol/L Screens the theoretical methyl-group drain from high-dose use
ALT and AST ALT < 25 U/L (men) / < 20 U/L (women) Detects the low-probability hepatic stress at higher doses
Fasting glucose and HbA1c Glucose 75–90 mg/dL; HbA1c < 5.4% Checks whether any metabolic effect materializes
Systolic blood pressure < 120 mmHg Captures the modest vascular signal most likely in those starting elevated

Cadence: Baseline before the first dose, repeat at ~8–12 weeks to assess response, then every 6–12 months for safety surveillance

Qualitative Assessment

  • Subjective energy and daytime fatigue
  • Exercise tolerance and recovery
  • Cognitive clarity and focus
  • Sleep quality
  • General sense of well-being